Hui K P
Singapore Med J. 1994 Jun;35(3):237-9.
Inhaled beta 2-adrenergic agonists have been used in the treatment of asthma since the 1970's. They are extremely effective bronchodilators in all situations of bronchoconstriction, and are generally well tolerated by patients. The recent advent of long-acting beta 2-adrenergic agonists will extend the clinical applications of this group of drugs. On the other hand, doubts have recently emerged on the safety of inhaled beta 2-adrenergic agonists. Recent well controlled studies also examined the manners whereby inhaled beta 2-adrenergic agonists are used in asthmatics, and the long term effects on lung functions. Although at least two decades have passed since the introduction of inhaled beta 2-adrenergic agonists, strategies on their optimum use have only emerged from these recent findings. This review briefly discusses as the most important developments leading to the rationalisation of the way inhaled beta 2-adrenergic agonists should be used in clinical asthma.
自20世纪70年代以来，吸入性β2肾上腺素能激动剂一直用于治疗哮喘。在所有支气管收缩的情况下，它们都是极其有效的支气管扩张剂，并且患者通常耐受性良好。长效β2肾上腺素能激动剂的近期出现将扩展这类药物的临床应用。另一方面，最近人们对吸入性β2肾上腺素能激动剂的安全性产生了怀疑。最近的严格对照研究还考察了吸入性β2肾上腺素能激动剂在哮喘患者中的使用方式以及对肺功能的长期影响。尽管自吸入性β2肾上腺素能激动剂问世以来至少已经过去了二十年，但这些最新研究结果才产生了关于其最佳使用的策略。本综述简要讨论了导致临床哮喘中吸入性β2肾上腺素能激动剂合理使用方式的最重要进展。
